- Home
- SLDB vs AVIR Comparison
SLDB vs AVIR Comparison
Compare SLDB & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLDB | AVIR |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.6M | 450.9M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SLDB | AVIR |
|---|---|---|
| Price | $7.18 | $5.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 1 |
| Target Price | ★ $16.36 | $10.00 |
| AVG Volume (30 Days) | ★ 867.5K | 262.4K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.97 | 3.00 |
| EPS | N/A | ★ N/A |
| Revenue | $8,094,000.00 | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.52 | $2.46 |
| 52 Week High | $8.87 | $6.45 |
Technical Indicators
Market Signals| Indicator | SLDB | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 41.26 | 50.29 |
| Support Level | $5.08 | $3.28 |
| Resistance Level | $7.35 | $6.37 |
| Average True Range (ATR) | 0.41 | 0.22 |
| MACD | -0.19 | -0.04 |
| Stochastic Oscillator | 10.22 | 48.65 |
Price Performance
Historical ComparisonAbout SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.